Remission Doubled With Risankizumab vs Ustekinumab in CD Remission Doubled With Risankizumab vs Ustekinumab in CD

Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a"once in a career" result, study authors say.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news